Hunan Yuneng New Energy Battery Material (301358.SZ) has submitted its H-share issuance and listing application to the Hong Kong Stock Exchange and published the application materials.
Hunan Yunan (301358.SZ) announced that on August 17, 2026, the company submitted an application to the Hong Kong Stock Exchange Limited (referred to as HKEX) for the issuance of overseas listed foreign shares (H shares) and for listing on the main board of HKEX. On the same day, the application materials for this issuance and listing were published on the HKEX website. The application materials were prepared and issued by the company in accordance with the requirements of the Securities and Futures Commission of Hong Kong and HKEX, and represent a draft version; the information contained may be updated and revised in a timely manner.
Hunan Yuneng New Energy Battery Material (301358.SZ) announced that it submitted an application to the Hong Kong Stock Exchange Limited (referred to as HKEx) for the issuance of overseas listed foreign shares (H shares) and for listing on the main board of the HKEx on August 17, 2026. On the same day, the application materials for this issuance and listing were published on the HKEx website. These application materials were prepared and issued by the company in accordance with the requirements of the Hong Kong Securities and Futures Commission and the HKEx, and are in draft form; the information contained may be updated and revised in a timely manner.
Related Articles
BIREN TECH (06082) achieved revenue in the first half of the year exceeding the total revenue for the entire year of 2025, with losses significantly narrowed by nearly 80%.
Shanghai Fosun Pharmaceutical (02196) subsidiary HENLIUS has signed a framework cooperation agreement and reached a licensing agreement with Sandoz AG.
INSILICO (03696) has been included in the MSCI Global Small Cap Index.
BIREN TECH (06082) achieved revenue in the first half of the year exceeding the total revenue for the entire year of 2025, with losses significantly narrowed by nearly 80%.
Shanghai Fosun Pharmaceutical (02196) subsidiary HENLIUS has signed a framework cooperation agreement and reached a licensing agreement with Sandoz AG.
INSILICO (03696) has been included in the MSCI Global Small Cap Index.
RECOMMEND
